SPOTLIGHT: Novartis: No more deals, no Roche sale


Two questions raised by yesterday's Novartis-Alcon announcement. Is the Swiss drug maker in the market for more deals? And might Novartis offload its one-third stake in Roche to pay for Alcon or some other acquisition. CEO Daniel Vasella (photo) answers both: No. Report | Report